Stay updated with breaking news from Abelacimab Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 12, 2023--
Fewer than 26% of Chinese Patients with Atrial Fibrillation are Prescribed an Anticoagulant, while in Japan Almost One-Third of Patients are Undertreated ...
Anthos Therapeutics has announced that Abelacimab has received FDA Fast Track Designation for the prevention of stroke and systemic embolism in patients with atrial fibrillation.
Abelacimab: First Factor XI Inhibitor to Enroll Patients in a Phase 3 Clinical Trial - read this article along with other careers information, tips and advice on BioSpace
/PRNewswire/ -- Anthos Therapeutics, a clinical-stage biopharma company developing innovative therapies for cardiovascular and metabolic diseases, today...